Drug Uses

Allegra-D is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion.

How Taken

The recommended dose of Allegra-D is one tablet twice daily for adults and children 12 years of age and older. It is recommended that the administration of Allegra-D with food should be avoided. A dose of one tablet once daily is recommended as the starting dose in patients with decreased renal function.

Warnings/Precautions

Do not take Allegra-D if you have taken a monoamine oxidase inhibitor (MAOI) in the last 14 days; asthma or another lung disease; diabetes; thyroid problems; glaucoma or increased pressure in the eye; urinary retention or an enlarged prostate; kidney or liver disease; or heart disease, high blood pressure, or an irregular heartbeat. You may not be able to take Allegra-D, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above. Allegra-D is in the FDA pregnancy category C. This means that it is not known whether it will be harmful to an unborn baby. Do not take Allegra-D without first talking to your doctor if you are pregnant or could become pregnant during treatment. It is not known if Allegra-D passes into breast milk. Do not take Allegra-D without first talking to your doctor if you are breast-feeding a baby. Allegra-D is not approved for use by children younger than 12 years of age.

Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not "double-up" the dose to catch up.

Possible Side Effects

Nausea, stomach upset, trouble sleeping, headache, or cold symptoms may occur. If these persist or worsen, notify your doctor promptly. Unlikely but report promptly: dizziness, mental/mood changes, fast heartbeat, fever. Tell your doctor immediately if any of these highly unlikely but very serious side effects occur: fainting, irregular heartbeat. Although drowsiness is very uncommon at usual doses under normal circumstances, be aware that drowsiness may occur and may affect the ability to perform tasks requiring alertness (e.g., driving). If you notice other effects not listed above, contact your doctor or pharmacist.

Storage

Store at room temperature between 68 and 77 degrees F (20-25 degrees C) away from sunlight and moisture.

Overdose

In large doses, Allegra-D may give rise to giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscular weakness and tenseness, anxiety, restlessness, and insomnia. You can present a toxic psychosis with delusions and hallucinations or you may develop cardiac arrhythmias, circulatory collapse, convulsions, coma, and respiratory failure.

More Information

Use caution when driving, operating machinery, or performing other hazardous activities. Allegra-D may cause dizziness. If you experience dizziness, avoid these activities. Do not take Allegra-D close to a dose of an antacid that contains aluminum or magnesium. These antacids may decrease the effects of Allegra-D.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Allegra-d at Wikipedia.org and other resources:

ALLEGRA--D 24 HOUR (Fexofenadine Hydrochloride And Pseudoephedrine Hydrochloride) Tablet, Film Coated [Sanofi-Aventis U.S. LLC]
Updated Date: Feb 25, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
Conclusions Clearly, the diagnosis and management of DCIS is highly complex with many unanswered questions, including the fundamental natural history of untreated disease. Because of the noninvasive nature of DCIS, coupled with its favorable prognosis, strong consideration should be given to elimination of the use of the anxiety-producing term "carcinoma" from the description of DCIS. The outcomes in women treated with available therapies are excellent. Thus, the primary question for future research must focus on the accurate identification of patient subsets diagnosed with DCIS, including those persons who may be managed with less therapeutic intervention without sacrificing the excellent outcomes presently achieved. Essential in this quest will be the development and validation of accura...

ALLEGRA-D (Fexofenadine And Pseudoephedrine) Tablet, Extended Release [Bryant Ranch Prepack]
Updated Date: Jan 28, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ALLEGRA D-12 HOUR (Fexofenadine Hcl And Pseudoephedrine Hcl ) Tablet, Extended Release [Caremark L.L.C.]
Updated Date: Jan 13, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Comorbidity, Hospitalization, and Mortality in COPD: Results from a Longitudinal Study
Abstract  We evaluated comorbidity, hospitalization, and mortality in chronic obstructive pulmonary disease (COPD), with special attention to risk factors for frequent hospitalizations (more than three during the follow-up period), and prognostic factors for death. Two hundred eighty-eight consecutive COPD patients admitted to respiratory medicine wards in four hospitals for acute exacerbation were enrolled from 1999 to 2000 in a prospective longitudinal study, and followed up until December 2007. The Charlson index without age was used to quantify comorbidity. Clinical and biochemical parameters and pulmonary function data were evaluated as potential predictive factors of mortality and hospitalization. FEV1, RV, PaO2, and PaCO2 were used to develop an index of respiratory f...